Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | PTGIR | P43119 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304682 | 0.86 | ALOX5 (0.43) | POLBSMN1; SMN2PPARAALOX5MAOA | |
| SCHEMBL1306105 | 0.85 | CYP1A2 (0.39) | POLBSMN1; SMN2PPARDPPARAALOX5 | |
| SCHEMBL1305429 | 0.85 | HDAC1 (0.46) | MAOBPOLBSMN1; SMN2ALOX5 | |
| SCHEMBL1305107 | 0.85 | L3MBTL1 (0.41) | POLBSMN1; SMN2ALOX5 | |
| SCHEMBL1304251 | 0.85 | LDHA (0.41) | POLBSMN1; SMN2ALOX5 | |
| SCHEMBL1305528 | 0.84 | SMN1; SMN2 (0.36) | MAOBPOLBSMN1; SMN2PPARDPPARA | |
| SCHEMBL1304996 | 0.84 | PTGIR (0.38) | POLBSMN1; SMN2PPARDPPARAPTGIR | |
| SCHEMBL1305197 | 0.84 | POLB (0.39) | POLBSMN1; SMN2ALOX5 | |
| SCHEMBL1304547 | 0.84 | MAPK1 (0.47) | POLBSMN1; SMN2 | |
| SCHEMBL1304618 | 0.82 | ITGB3 (0.41) | MAOBPOLBSMN1; SMN2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | claimed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | claimed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | claimed |
| US-8053449-B2 | Method for inhibiting AGE complex formation | Cell Viable Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| US-20080076804-A1 | METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION | Cell Viable Corporation | 2008-03-27 | — | — | US | disclosed |
| US-20070099966-A1 | Device and Method for Inhibiting AGE Complex Formation | Cell Viable Corporation | 2007-05-03 | — | — | US | disclosed |
| WO-2007044309-A2 | DEVICE AND METHOD FOR INHIBITING AGE COMPLEX FORMATION | VASIX CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | disclosed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | disclosed |